Membranous Nephropathy: Approaches to Treatment

Area of Science:

• Nephrology
• Immunology
• Pathogenesis of kidney disease

Background:

• Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
• Advances in understanding MN pathogenesis include identifying target antigens like M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A.

Purpose of the Study:

• To review the mechanisms underlying MN pathogenesis.
• To discuss current and emerging treatment approaches for MN.

Main Methods:

• Review of current literature on MN pathogenesis and treatment.
• Analysis of novel therapeutic strategies and biomarkers.

Main Results:

• Identification of key antigens and biomarkers has improved MN diagnosis and risk stratification.
• B-cell depletion (e.g., rituximab) shows promise as an initial therapy.
• Adrenocorticotropic hormone (ACTH) is a potential option for refractory cases.

Conclusions:

• New biomarkers aid in personalized treatment strategies for MN.
• B-cell depletion is a supported initial treatment for nephrotic MN.
• ACTH should be considered for patients unresponsive to conventional therapies.